市場調查報告書
商品編碼
1064773
注意力不足過動障礙的全球市場:2021年~2027年Attention Deficit Hyperactivity Disorder Drug Market 2021-2027 |
全球注意力不足過動障礙的市場規模,在預測期間內預計以大幅度的年複合成長率擴大。新生兒中早產兒數增加,推動該市場的成長。根據馬里蘭大學醫療中心(UMMC),現在有20%的早產兒罹患這個疾病。全球的政府,關注含注意力不足過動症(ADHD)的許多精神障礙罹患的人們增加。政府對該疾病治療的關心,將是更加牽引全球市場。
本報告提供全球注意力不足過動障礙市場相關調查,市場概要,以及各藥物類型,各年齡群,各流通管道,各地區的趨勢,及加入此市場的主要企業簡介等資訊。
Global Attention deficit hyperactivity disorder drug market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce) by Age Group (Children and Adults), and Forecast (2020-2026)
The global attention deficit hyperactivity disorder drug market is anticipated to grow at a considerable CAGR during the forecast period. The increase in the number of pre-term deliveries of newborns is contributing the growth of the global attention deficit hyperactivity disorder drug market. According to the University of Maryland Medical Center (UMMC), this disease affects 20% of prematurely born babies currently. Governments across the globe are paying attention to the growing number of people suffering from a number of psychological disorders, including attention deficit hyperactivity disorder (ADHD). This focus of government towards treatment of such disease is further likely to drive the global market.
The global attention deficit hyperactivity disorder drug market is segmented based on drug type, distribution channel, and age group. Based on drug type, the attention deficit hyperactivity disorder drug market is segmented into stimulants and non- stimulants. Based on distribution channel, the attention deficit hyperactivity disorder drug market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. Based on age group, the attention deficit hyperactivity disorder drug market is segmented into children and adults.
Geographically, the global attention deficit hyperactivity disorder drug market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. Some of the companies operating in the global attention deficit hyperactivity disorder drug market include Pfizer Inc., Eli Lilly and Company., Novartis AG., GlaxoSmithKline PLC., Mallinckrodt Pharmaceuticals., Hisamitsu Pharmaceutical Co., Inc., and Johnson & Johnson., among others.
Market Segmentation
The Report Covers